Aardvark Therapeutics (NASDAQ:AARD) Earns Outperform Rating from Analysts at Royal Bank of Canada

Equities researchers at Royal Bank of Canada began coverage on shares of Aardvark Therapeutics (NASDAQ:AARD) in a report released on Monday,Briefing.com Automated Import reports. The firm set an “outperform” rating and a $21.00 price target on the stock. Royal Bank of Canada’s price objective would indicate a potential upside of 107.31% from the company’s current price.

Separately, Cantor Fitzgerald started coverage on Aardvark Therapeutics in a research note on Monday. They set an “overweight” rating and a $50.00 price target for the company.

Aardvark Therapeutics Stock Performance

AARD opened at $10.13 on Monday. Aardvark Therapeutics has a 52-week low of $9.21 and a 52-week high of $19.58.

Insider Buying and Selling

In other news, CEO Tien-Li Lee purchased 16,542 shares of the business’s stock in a transaction on Friday, February 14th. The stock was purchased at an average price of $16.00 per share, with a total value of $264,672.00. Following the acquisition, the chief executive officer now directly owns 1,496,175 shares in the company, valued at approximately $23,938,800. The trade was a 1.12 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Nelson Sun purchased 10,000 shares of the business’s stock in a transaction on Friday, February 14th. The stock was purchased at an average cost of $16.00 per share, with a total value of $160,000.00. Following the acquisition, the chief financial officer now owns 99,484 shares in the company, valued at approximately $1,591,744. This represents a 11.18 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Aardvark Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.